 |
21 Diseases |  |
3 Trials |
|
3 Trials |  |
166 News |  |
| 12» |
- lucitanib (E 3810) / Clovis, Servier
Efficacy and safety of lucitanib (AL3810) in second or subsequent-line treatment of advanced recurrent or metastatic thymic carcinoma: A randomized, double-blind, placebo-controlled multicenter phase II trial (Hall 406) - Oct 15, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1318;
No grade 4/5 TRAEs were observed. Conclusions This study suggests that Lucitanib may have significant clinical benefit and has acceptable safety for patients with advanced recurrent or metastatic thymic carcinoma.
- | lucitanib (E 3810) / Clovis, Servier
New P1/2 trial, Metastases: An open-lable phase Ib/II study, Lucitanib combined with Toripalimab in the treatment of advanced recurrent or metastatic solid tumors (EUDRACT) - Sep 20, 2024
P1/2, N=180, Completed, Sponsor: Sun Yat-sen University Cancer Center; Haihe Biopharma Co.,Ltd.
- lucitanib (E 3810) / Clovis, Servier
The anti-angiogenic multi-kinase inhibitor AL3810 exerts differential effects on tumor infiltrating CD8+ T cell subsets and cooperatively enhances the anti-tumor effects of PD-1 blockade therapy (Exhibition Hall) - Sep 7, 2024 - Abstract #EORTCNCIAACR2024EORTC_NCI_AACR_97;
Unless they are part of the media programme, embargoed or not consented, all abstracts will be released on 9 October 2024. All other abstracts will be released on the day of presentation.
- || lucitanib (E 3810) / Clovis, Servier, dovitinib (TKI258) / Novartis, Oncoheroes, Balversa (erdafitinib) / J&J
Review, Journal: Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer: mechanisms and role in endocrine resistance. (Pubmed Central) - Jul 23, 2024
In conclusion, targeting FGFR signaling in ER+ breast cancer presents both challenges and opportunities. A deeper understanding of the molecular mechanisms and resistance pathways is crucial for the successful integration of FGFR inhibitors into clinical practice, aiming to improve outcomes for patients with endocrine-resistant breast cancer.
- lucitanib (E 3810) / Clovis, Servier
Targeting angiogenesis for improved survival in mantle cell lymphoma (Section 22) - Mar 5, 2024 - Abstract #AACR2024AACR_5270;
Lucitanib treatment significantly prolonged median overall survival significantly in the systemic MCL model. Our data demonstrates that targeting angiogenesis in MCL can provide therapeutic benefits, as demonstrated in preclinical MCL models.
- Rubraca (rucaparib) / Pharma& Schweiz
Phase classification, Combination therapy: A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) (clinicaltrials.gov) - Jan 16, 2024
P1/2, N=25, Terminated, Sponsor: pharmaand GmbH
Our data demonstrates that targeting angiogenesis in MCL can provide therapeutic benefits, as demonstrated in preclinical MCL models. Phase classification: P1b/2 --> P1/2
- |||||| lucitanib (E 3810) / Clovis, Servier
Trial suspension: ENGOT-GYN3: A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor (clinicaltrials.gov) - Dec 20, 2022
P1b/2, N=227, Suspended, Sponsor: Clovis Oncology, Inc.
Phase classification: P1b/2 --> P1/2 Active, not recruiting --> Suspended
- | Biomarker, Journal, Gene Signature: Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma. (Pubmed Central) - Oct 13, 2022
Using available genetic atlas data, potential drug candidates for treatment of PDAC were identified based on differentially expressed genes, protein interaction analysis and connectivity mapping. These results may help focus efforts on identifying targeted agents with potential therapeutic efficacy for evaluation in prospective clinical trials of patients with PDAC.
- | lucitanib (E 3810) / Clovis, Servier
Journal, PD(L)-1 Biomarker, IO biomarker: The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models. (Pubmed Central) - Sep 10, 2022
These data indicate that lucitanib can modulate vascular and immune components of the tumor microenvironment and cooperate with immunotherapy to enhance antitumor efficacy. They support the clinical development of lucitanib combined with immune pathway modulators to treat cancer.
- lucitanib (E 3810) / Clovis, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
Phase 2 Results From the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): Efficacy and Safety of Lucitanib + Nivolumab in Patients With Advanced Gynaecological Malignancies (Alpha 3+4) - Sep 6, 2022 - Abstract #ESGO2022ESGO_389;
P1b/2
They support the clinical development of lucitanib combined with immune pathway modulators to treat cancer. Abstract is embargoed at this time.
- || lucitanib (E 3810) / Clovis, Servier
PK/PD data, Journal: Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer. (Pubmed Central) - Aug 26, 2022
P1/2, P2
The PopPK model adequately described lucitanib pharmacokinetics. High between-subject pharmacokinetic variability supports a safety-based dose-titration strategy currently being used in an ongoing clinical study of lucitanib to optimize drug exposure and clinical benefit.
- | Rubraca (rucaparib) / Pharma& Schweiz
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) (clinicaltrials.gov) - Jul 28, 2022
P1b/2, N=25, Terminated, Sponsor: Clovis Oncology, Inc.
High between-subject pharmacokinetic variability supports a safety-based dose-titration strategy currently being used in an ongoing clinical study of lucitanib to optimize drug exposure and clinical benefit. N=329 --> 25 | Trial completion date: Mar 2024 --> Apr 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Mar 2022; Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.
- || lucitanib (E 3810) / Clovis, Servier
P1 data, Journal: A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma. (Pubmed Central) - Jun 11, 2022
P1
Patients who responded to lucitanib treatment generally achieved a long DoR. Lucitanib is now being evaluated in phase II/III studies.
- || lucitanib (E 3810) / Clovis, Servier
Would these be the good sign for $CLVS 🤔 #ASCO22 FAP-2286 https://t.co/n3jCp1qnua Lucitanib https://t.co/zAP5KRBw5O (Twitter) - Jun 6, 2022
- |||||| lucitanib (E 3810) / Clovis, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
Biomarker, Clinical, P1 data, IO biomarker: The combination of #Immunotherapy and #antiangiogenics has clear rationale. Phase 1 trial of lucitanib and nivolumab demonstrated clinical activity in #GynecologicCancers but it is clear that biomarkers are needed for selection. #gyncsm #ASCO22 (Twitter) - Jun 4, 2022
- lucitanib (E 3810) / Clovis, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO). (Available On Demand; 396) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5459;
P1b/2
Stage 2 enrollment has continued in the CC cohort. Biomarker analysis is ongoing, and more mature efficacy and safety data will be presented at the meeting.
- | lucitanib (E 3810) / Clovis, Servier
Journal: PI3Kα inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma. (Pubmed Central) - Mar 24, 2022
Biomarker analysis is ongoing, and more mature efficacy and safety data will be presented at the meeting. No abstract available
- lucitanib (E 3810) / Clovis, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (Phoenix Convention Center-WB 301 ABC) - Jan 26, 2022 - Abstract #SGO2022SGO_626;
P1b/2
- ||| lucitanib (E 3810) / Clovis, Servier
Enrollment closed: ENGOT-GYN3: A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor (clinicaltrials.gov) - Jan 21, 2022
P1b/2, N=227, Active, not recruiting, Sponsor: Clovis Oncology, Inc.
No abstract available Recruiting --> Active, not recruiting
- || lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier
@GSK should acquire $clvs $560M MCAP 3 assets in portfolio 1) radionuclide lutetium-177 (177Lu) which @Novartis paid $2.1B to acquired $ECYT 2) ucaparib PARP approved in 3 indication 3) Lucitanib (Twitter) - Jul 8, 2021
- lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2156;
P1b/2
Ph1b data suggest that lucitanib + nivolumab has promising signs of antitumor activity . A safety-based dose-titration strategy appears feasible with manageable toxicity, based on experience from the Ph2 OC cohort to date; efficacy data from this cohort will also be presented.
- lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Rubraca (rucaparib) / Clovis
[VIRTUAL] Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_909;
P1b/2
Initial findings suggest that rucaparib + lucitanib has an acceptable safety profile . The safety and efficacy of the combination are being further evaluated.
- || lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier
Great work ! We had a trial with Lucitanib but it didn’t go very well.. (Twitter) - Apr 14, 2021
- ||| Rubraca (rucaparib) / Pharma& Schweiz
Enrollment closed, Combination therapy: A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) (clinicaltrials.gov) - Apr 13, 2021
P1b/2, N=329, Active, not recruiting, Sponsor: Clovis Oncology, Inc.
The safety and efficacy of the combination are being further evaluated. Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / BMS
Enrollment change, Trial withdrawal: CheckMate 79X: A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy (clinicaltrials.gov) - Feb 17, 2021
P1/2, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting N=660 --> 0 | Not yet recruiting --> Withdrawn
- | lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier
Journal: A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated. (Pubmed Central) - Feb 4, 2021
We newly proposed a pentapeptide mn with superb αvβ3-binding affinity and tailored AL3810-loaded mn-modified liposome that afforded impervious blood circulation, targeting ability, and glioma therapeutic expertise as vastly alleviated immune opsonization on the underpinning of the finite antibodies and complements assembly. Stemming from attenuated immunogenicity, peptide mn strengthened liposome functions as a promising nanocarrier platform for molecular targeting agents.
- || Review, Journal: The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. (Pubmed Central) - Jan 6, 2021
Nintedanib, pazopanib, pemigatinib, rogaratinib, fisogatinib, and PRN1371 are FGFR inhibitors lacking drug-enzyme crystal structures...The development of FGFR inhibitors has lagged behind those of other receptor protein-tyrosine kinases. However, the FDA approval of erdafitinib for the treatment of urinary bladder cancers may stimulate additional work targeting the many other FGFR-driven neoplasms.
- ||||| lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Video: We had the pleasure of speaking with Dr. Hamilton - LIO-1: Phase 2 study and Initial clinical experience of lucitanib + nivolumab - Erika P. Hamilton, MD @ErikaHamilton9 @SarahCannonDocs #ESMO20 #breastcancer #bcsm #Cancer Link To FULL Video: https://t.co/u9fz8wsuOT (Twitter) - Dec 29, 2020
- || lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier
Biomarker, P2 data, Journal: Lucitanib for the treatment of HR/ HER2 metastatic breast cancer: results from the multicohort phase II FINESSE study. (Pubmed Central) - Oct 3, 2020
Lucitanib had modest antitumor activity and significant hypertension-related toxicity in patients with HR/ HER2 MBC. Although based on small sample sizes, exploratory biomarker analyses suggested patients with high FGFR1 amplification or expression might derive greater benefit.
- ||||| lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Video: LIO-1: Phase 2 study and Initial clinical experience of lucitanib + nivolumab - Erika P. Hamilton, MD @ErikaHamilton9 @SarahCannonDocs #ESMO20 #breastcancer #bcsm #Cancer Link to FULL video: https://t.co/u9fz8wsuOT (Twitter) - Sep 30, 2020
- lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier
[VIRTUAL] A phase-Ib study of lucitanib (AL3810) in a cohort of patients with recurrent and metastatic nasopharyngeal carcinoma (NPC) (Channel 3) - Sep 24, 2020 - Abstract #ESMOAsia2020ESMO_Asia_171;
P1
Funding: Shanghai HaiHe Pharmaceutical Co., Ltd. Clinical trial identification: NCT03260179.
- |||| lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Erika P. Hamilton, MD @ErikaHamilton9 @SarahCannonDocs #ESMO20 #breastcancer LIO-1: A Phase 2 study and Initial clinical experience of lucitanib + nivolumab https://t.co/IjbeskfcoW (Twitter) - Sep 23, 2020
- |||| lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, P1/2 data: Initial Clinical Experience Of Lucitanib + Nivolumab In Advanced Metastatic Solid Tumours: Data From The Phase 1b/2 LIO-1 Study will be presented in @ErikaHamilton9’s #ESMO20 poster session, available on demand NOW. (Twitter) - Sep 20, 2020
- |||| lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: The first patient has been enrolled on the phase 2 portion of the LIO-1 trial, which will examine the combination of lucitanib plus nivolumab in those with gynecologic cancers. @ErikaHamilton9 @SarahCannonDocs #gynca https://t.co/5j8wgJYs4D (Twitter) - Sep 15, 2020
- |||| lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
.@ErikaHamilton9, of @SarahCannonDocs, discusses the phase 2 portion of the LIO-1 trial, which will examine the combination of lucitanib plus nivolumab in those with gynecologic cancers. #gynca https://t.co/9h7RfQtINk (Twitter) - Sep 14, 2020
- ||| lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
Lucitanib/Nivolumab Combo Enters Phase 2 Evaluation for Gynecologic Cancers @ErikaHamilton9 @SarahCannonDocs #gynca https://t.co/7F1djNFKwP (Twitter) - Sep 12, 2020
- | lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier
Clvs lucitanib data what to expect? (Twitter) - Sep 11, 2020
- ||| lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
P1/2 data: $CLVS $bms @ScienceAtBMS #ESMO2020 abstracts: 1) PH 1B/2 Lucitanib + Nivolumab 2)PH 2 Lucitanib + Nivolumab (Twitter) - Sep 9, 2020
- |||| lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier
@Takeda acquired @ariadpharmeuticals for 5.2B for small molecule FGFR inhibitors which @ClovisOncology $clvs is developing Lucitanib (small molecule FGFR) targeting mutations (ALK, EGFR, BRAF) one of the kind small molecule. @ScienceAtBMS @pfizer @GileadSciences @abbvie @sanofi (Twitter) - Sep 8, 2020
- lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] LIO-1: A phase II study of lucitanib + nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1708;
P1b/2
Funding: Clovis Oncology, Inc. Clinical trial identification: NCT04042116.
- lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Initial clinical experience of lucitanib + nivolumab in advanced metastatic solid tumours: Data from the phase Ib/II LIO-1 study (CO-3810-101; NCT04042116) (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_837;
P1b/2
Funding: Clovis Oncology, Inc. Clinical trial identification: NCT04042116.
- ||| Opdivo (nivolumab) / BMS
Trial completion date, Trial initiation date, Trial primary completion date: CheckMate 79X: A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy (clinicaltrials.gov) - Jun 25, 2020
P1/2, N=660, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Clinical trial identification: NCT04042116. Trial completion date: Jul 2025 --> May 2026 | Initiation date: Aug 2020 --> Apr 2021 | Trial primary completion date: Jul 2024 --> Dec 2023
- ||| lucitanib (E 3810) / Clovis, HaiHe Pharma, Servier
Maybe adding AKT inhibitor to Lucitanib ? https://t.co/ZjKzwtr8dk (Twitter) - May 30, 2020
- || lucitanib (E 3810) / Clovis, HaiHe Pharma, Servier
Hello Sir - what do you think of Lucitanib ... are the results so far promising ? (Twitter) - May 23, 2020
- lucitanib (E 3810) / Clovis, HaiHe Pharma, Servier, ALKS 4230 / Alkermes
The combination of a mouse ortholog of ALKS 4230, a selective agonist of the intermediate affinity IL-2 receptor, and the angiogenesis inhibitor lucitanib enhances antitumor activity (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_679;
The combination led to a significant (p<0.05) increase in intratumoral CD8+ T cells and dendritic cells (CD11c+F4/80-), together with a reduction in tumor-associated macrophages (CD11b+F4/80+). The combination treatment elicited a distinct gene expression profile in tumors by RNA-Seq, merging the immunostimulatory effects of RDB 1462 with the anti-angiogenic effects of lucitanib.The combination of an intermediate affinity IL-2R-selective cytokine and an angiogenesis inhibitor resulted in durable dose-dependent antitumor efficacy in the MC38 mouse tumor model.
- lucitanib (E 3810) / Clovis, HaiHe Pharma, Servier
Application of machine learning and grid search approaches to minimize lucitanib pharmacokinetic variability following different dosing regimens (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_3977;
Compared with a fixed-dose regimen, body weight-based regimens showed a small reduction in PK variability for lucitanib in the overall population, suggesting that there is limited benefit with body weight-based dosing. Dose optimization will be further evaluated with a growing understanding of the target therapeutic range and exposure-response relationships.
- lucitanib (E 3810) / Clovis, HaiHe Pharma, Servier
[VIRTUAL] An open-label phase Ib study to determine safety and preliminary efficacy of oral Lucitanib (AL3810) in patients with locally advanced or metastatic gastric, hepatocellular, nasopharyngeal carcinoma, malignant biliary, and thymic tumors. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3650;
Lucitanib exhibited better efficacy profile when administrated 10mg QD continuously. Further safety and efficacy of lucitanib is being evaluated in phase II/III studies.
- lucitanib (E 3810) / Clovis, HaiHe Pharma, Servier, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Initial clinical experience of lucitanib in combination with nivolumab in patients (Pts) with an advanced metastatic solid tumor: Data from a phase Ib/II study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3649;